In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...

The most negatively impacted sectors are frozen, refrigerated, general food and beverages. Circana found GLP-1 users’ monthly ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...